|
Peptide
tools for intracellular drug delivery
Most of the currently recognised CPPs are of cationic
nature and derived from viral, insect or mammalian proteins
endowed with membrane translocation properties. The exact
mechanisms underlying the translocation of CPPs across
the cellular membrane are still poorly understood, says
Anantha Naik Nagappa
|
Editorial
Unite against
aids
Edit Article
Biotech
segment: Moving ahead of pharma industry
|
|
Herbal
answer to free radical rebellion
Many of the antioxidant herbs are promising candidates
in the treatment of cancer, atherosclerosis, diabetes,
antimicrobial and anti-inflammatory agents and those
with neuroprotective abilities, says Dr S A Kolhapure
|
Solutions
for all round growth
IT-enabled solutions have paid huge dividends for pharmaceutical
companies, says Raghu Ram N C
|
|
‘India
has highly qualified clinicians providing excellent
clinical care’
Dr Ravi Anand, MD, a resident of Switzerland, an independent
consultant specialises in the development and commercialisation
of New Chemical Entities (NCE) for Central Nervous System
(CNS) disorders. He is a consultant to pharmaceutical
and biotech companies, contract research organisations
(CROs), universities and financial institutions. Dr
Anand in an exclusive with N V Ramamurthy discusses
various issues in clinical trials. Excerpts:
|
